Department of Periodontology, Faculty of Dentistry, Gazi University, Ankara, Turkey.
J Periodontol. 2018 Oct;89(10):1174-1183. doi: 10.1002/JPER.17-0381. Epub 2018 Aug 29.
Flurbiprofen which is a non-steroidal anti-inflammatory drug (NSAID), has been safely used for the control of postoperative patient's morbidity after periodontal plastic surgeries requiring palatal graft harvesting, but there is little information on the efficacy of topical use. The aim of the study was to evaluate whether patient pain perception was reduced and patient morbidity was improved by using oral spray of flurbiprofen after palatal graft harvesting.
Forty-eight patients (21 males and 27 females), scheduled for subepithelial connective tissue graft (SCTG) and free gingival graft (FGG) requiring periodontal plastic surgeries were selected. The patients were randomly assigned to each group and used oral spray of flurbiprofen or placebo three times a day for a week. The palatal donor area was evaluated at 1, 3, 7, 14, 21, 28, 42, and 56-day follow-up after the surgery for postoperative pain, patients' discomfort, complete epithelialization, changes in dietary habits, burning sensation, color match, the amount of systemic analgesic consumption and the presence of delayed bleeding. Wound healing scores were recorded at 14-day follow up.
The prevalance of complete epithelialization was significantly higher in the placebo-FGG group than flurbiprofen-FGG group at 21 days postoperatively (P < 0.05), while there was no significant alteration for both flurbiprofen-SCTG and placebo-SCTG groups at any follow-up periods. In flurbiprofen-FGG group, significant improvements were observed for postoperative pain, patients' discomfort and burning sensation at 14 days postoperatively (P < 0.05).
Oral flurbiprofen spray reduces patient's morbidity, however it might have negative effects on epithelialization of secondary wound healing after FGG operations.
氟比洛芬是一种非甾体抗炎药（NSAID），已安全用于控制需要腭部移植物采集的牙周整形手术后患者的发病率，但关于其局部应用效果的信息较少。本研究旨在评估在腭部移植物采集后使用氟比洛芬口腔喷雾剂是否可以减轻患者的疼痛感知并改善患者的发病率。
选择 48 名（21 名男性和 27 名女性）计划进行牙周整形手术的患者，他们需要进行上皮下结缔组织移植（SCTG）和游离牙龈移植（FGG）。患者被随机分配到每组，并在一周内每天使用氟比洛芬或安慰剂口腔喷雾剂三次。在手术后 1、3、7、14、21、28、42 和 56 天对腭部供区进行评估，以评估术后疼痛、患者不适、完全上皮化、饮食习惯改变、烧灼感、颜色匹配、全身镇痛药使用量和延迟出血的情况。在 14 天随访时记录伤口愈合评分。
在术后 21 天，安慰剂-FGG 组的完全上皮化发生率明显高于氟比洛芬-FGG 组（P<0.05），而氟比洛芬-SCTG 和安慰剂-SCTG 组在任何随访期间均无明显变化。在氟比洛芬-FGG 组中，术后 14 天患者的疼痛、不适和烧灼感明显改善（P<0.05）。
口腔氟比洛芬喷雾剂可减轻患者的发病率，但可能对 FGG 手术后的二次伤口愈合的上皮化产生负面影响。
